Merck's lambrolizumab wins breakthrough status for melanoma

04/25/2013 | Fox Business

The FDA granted breakthrough therapy status to Merck's experimental antibody drug lambrolizumab as a treatment for advanced melanoma. Lambrolizumab, which targets the programmed death receptor, is also being evaluated as a treatment for nonsmall-cell lung cancer.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park